

# Genomics and Transcriptomics in the Clinical Microbiology Laboratory

**Randall J. Olsen, M.D., Ph.D.**

Director, Molecular Diagnostics Laboratory

Director, Special Testing Laboratory

Co-Director, Microbiology Laboratory

Department of Pathology and Genomic Medicine

Houston Methodist Hospital and Research Institute

Houston, Texas, USA

**Association of Public Health Laboratories**

**June 6, 2016**

HOUSTON  
**Methodist**<sup>SM</sup>  
RESEARCH INSTITUTE

- Rapid identification of pathogenic organisms
  - Detection from patient specimens or primary cultures
  - Inferred antimicrobial susceptibility and virulence
- 

- PCR/amplification based tests
- MALDI-TOF mass spectrometry
- Next Generation Sequencing

*Genomic data may inform treatment decisions to improve patient care*

# New technologies: Whole genome sequencing

- **First bacteria genome**  
*H. influenzae* strain Rd  
**Published in 1995**  
**> 1 year**  
**> 1 million US dollars**



Flow cell for the Illumina MiSeq sequencer.

- **Today,**  
1 or a few genomes can be generated within 1 day  
384 genomes can be generated in 2 weeks for ~\$50/each
- **The \$10 microorganism genome will soon be a reality**

## A day in the life of the microbiology laboratory

- **130 samples collected from 116 patient cultures on a single day**
- **Aerobic bacteria, anaerobic bacteria, acid-fast bacilli and fungi**
- **Isolated colonies and mixed samples**

# Results: A day in the life of the microbiology laboratory

## Whole genome sequencing:

- Identified most “unknown” organisms (88.5% concordance with reference method)
- Detected *Mycobacterium species* in two samples 10 days before conventional methods
- Identified most organisms present in mixed samples
- Detected organisms not recovered by our routine culture based methods (e.g. *Gardnerella vaginalis*)

# Challenges: A day in the life of the microbiology laboratory

## Whole genome sequencing could not identify:

- 10 organisms due to their absence from the reference database
- The lack of a comprehensive database of human pathogens was particularly problematic for medically important fungi

➤ *Important Research Opportunity*

# Whole genome sequencing of microorganisms in our clinical lab

## First run as a routine clinical test: June 26, 2013

- **~400 genome sequences analyzed in the validation study**
- **Bacteria, fungi and influenza A virus**
- **>600 genomes generated as an ordered test**

# Whole genome sequencing of microorganisms in our clinical lab

## Routine cases

- **Organisms that are slow growing, difficult to identify or can not be identified using culture based techniques**
  - *Mycobacterium species* and fungus
- **Organisms requiring further classification for optimal patient care or public health efforts**
  - Serotyping *Salmonella enterica* and *Neisseria meningitidis*

# Whole genome sequencing of microorganisms in our clinical lab

## Special cases


- **Organisms with unusual antimicrobial resistance**
  - **Investigated the molecular basis of ceftaroline resistance in *S. aureus***  
(Long, et al., *Antimicrob Agents Chemother*, 2014)

# High level resistance to ceftaroline

- We investigated a highly ceftaroline resistant strain of *S. aureus* recovered from a cystic fibrosis patient.
- Ceftaroline is a recently approved anti-staphylococcal agent with no reports of highly resistant stains.
- Some reports suggest that ceftaroline has a structure making development of resistance unlikely.

***We used whole genome sequencing to discover the molecular basis of ceftaroline resistance***

# Whole genome sequencing identified the genetic basis of ceftaroline resistance



**Genome sequencing identified mutations altering 2 amino acids in the active site of the penicillin binding protein 2a.**


**These data provide a molecular explanation for an unexpected antibiotic resistance phenotype.**

## Special cases

- **Organisms causing unusually severe or unexpected clinical presentations**
- **Investigated a fatal anthrax-like infection**  
(Wright, et al., *Arch Pathol Lab Med*, 2011)

# Previously healthy male with severe pneumonia and death within 72 h

**BAL on presentation**  
with extremely high numbers  
of rod-shaped bacteria



**Blood culture**  
pure culture of  
*Bacillus cereus* group organisms



# The *Bacillus cereus* group troika

***Bacillus anthracis***

***Bacillus cereus***

***Bacillus thuringiensis***

- Very closely related
- Difficult to classify using conventional microbiology techniques
- Mobile genetic elements (plasmids) are crucial for virulence


***We performed whole genome sequencing to investigate the molecular basis of this severe, rapidly fatal infection.***

# Whole genome sequencing identified the causative agent

- **Identified etiologic agent of the fatal Anthrax-like infection**
  - *B. cereus* with anthrax toxin genes, not *B. anthracis*
- **Ruled out the likelihood of bioterrorism**
  - No foreign DNA or evidence of other genetic manipulation
- **Guided infection control response**
  - No cases of secondary transmission


# Whole genome sequencing of outbreak pathogens

- **Outbreaks caused by naturally occurring or nefariously introduced microbial agents can rapidly decimate a population and cause a public health emergency.**
- **Large hospital based laboratories must be highly vigilant since they will likely be the first to recover the pathogen and perhaps recognize the potential for an outbreak.**
- **To this end, our clinical laboratory has validated and implemented whole genome sequencing as a clinical test.**




To assess our clinical laboratory's ability to rapidly respond to a large-scale emergency outbreak scenario, we contrived a "fire drill" using *emm59* Group A Streptococcus (GAS) strains collected by the US CDC.

- Serotype *emm59* GAS are an uncommon cause of human infection.
- A hypervirulent *emm59* clone recently emerged to cause hundreds of severe invasive infections across Canada and some parts of the US.
- Epidemiology studies conducted by the US CDC discovered an increased number of *emm59* GAS infections in the state of Minnesota.



**This study was constructed as a best case scenario:**

- 1. A high quality, closed, well-annotated, *emm59* GAS genome is publically available.**
- 2. The research team was familiar with this organism and had sequenced the genome of >500 strains recovered in Canada.**
- 3. Compared to other pathogens such as *K. pneumoniae*, GAS has a small genome and few mobile genetic elements.**
- 4. The US CDC had already collected the strains, and collaborators at the Minnesota Department of Public Health were ready to act on the genomic findings.**




**Are these US infections clonally related to the *emm59* GAS outbreak in Canada?**

**If so, what additional information can be generated in the clinical laboratory to guide patient care?**


***We performed whole genome sequencing, genome-wide transcript analysis and mouse virulence studies.***

# Timeline of the rapid-response exercise performed in our clinical laboratory



***Can we generate actionable information in a clinically relevant timeframe?***

# Whole genome sequence analysis of *emm59* GAS strains recovered in the United States



**Within 3 days, we discovered:**


**US strains are clonally related to Canadian outbreak strains.**

**Five sets of genomically indistinguishable strains.**

**Strains recovered in Minnesota are allied with strains from two different Canadian provinces.**

***The genomics data informed the epidemiology investigation!***

# Gene expression analysis of *emm59* GAS strains recovered in the United States





## 3 strains selected for RNAseq:

1. Strains recovered from Minnesota to emulate a regional outbreak.
2. Strains were located on different branches of the phylogenetic tree.
3. Strains had wild-type alleles for all major regulators.

***Within 8 days, we demonstrated the US strains have a highly similar genome-wide expression profile; however, they were not identical!***

# Gene expression analysis of *emm59* GAS strains recovered in the United States




## RNAseq revealed that:

-Strain MGAS26494 unexpectedly overexpresses the genes encoding the hyaluronic acid capsule virulence factor.

-On reanalysis of the genome sequence, we discovered a deletion in the *hasABC* promoter region.

***The transcriptomics data informed the genome analysis!***

# Gene expression analysis of *emm59* GAS strains recovered in the United States



## RNAseq also revealed that:



-Strain MGAS26494 overexpresses the genes encoding the *yesM/N* two component system.

-On reanalysis of the genome sequence, we discovered a mixed population, with ~50% of reads having a polymorphism in *yesM/N*.

-This mutation also explains the altered expression of 8 genes regulated by YesM/N.

***The transcriptomics data informed the genome analysis!***

# Mouse model of invasive infection using *emm59* GAS strains recovered in the United States



***The animal model could be used to rapidly investigate strain virulence or test new vaccines, diagnostics and therapies!***

- **Whole genome sequencing can be readily integrated into the routine workflow of a clinical laboratory to support patient care decisions.**
- **We created a standard operating procedure for using genomics, transcriptomics and animal studies as part of our disaster preparedness plan.**
- **We implemented process improvements.**

# Acknowledgments

## Houston Methodist Hospital

Steve Beres, PhD

Connie Cantu

Priyanka Kachroo, PhD

S. Wesley Long, MD, PhD

James Musser, MD, PhD

Misu Sanson, MD

Chandni Valson

## Centers for Disease Control and Prevention

Chris Van Beneden, MD, MPH

## Public Health Ontario

Nahuel Fittipaldi

## Minnesota Department of Health

Ruth Lynfield, MD

Kathryn Como-Sabetti, MPH